materialise

innovators you can count on

Q3 2022 Financial Results

Conference Call October 27, 2022

> www.materialise.com NASDAQ: MTLS



Safe Harbor Summary

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations, plans, objectives, strategies and prospects, both financial and business, including statements concerning, among other things, our current estimates for fiscal 2022 revenue and Adjusted EBITDA, results of operations, cash needs, capital expenditures, expenses, financial condition, liquidity, prospects, growth and strategies (including how our business, results of operations and financial condition could be impacted by the ongoing military conflict between Ukraine and Russia and economic sanctions related thereto), and the trends and competition that may affect the markets, industry or us. Such statements are subject to known and unknown uncertainties and risks. When used in this press release, the words "estimate," "expect," "anticipate," "project," "plan," "intend," "believe," "forecast," "will," "may," "could," "might," "aim," "should," and variations of such words or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the expectations of management under current assumptions at the time of fis press release. These expectations, beliefs and projections are expressed in good faith and the Company believes there is a reasonable basis for them. However, the Company cannot offer any assurance that our expectations, beliefs and uncertainties because they relate to events, competitive dynamics and industry change, and depend on projections will actually be achieved. By their nature, forward-looking statements involve risks and uncertainties that may or court on the future or may occur on shorter timelines than anticipated. We caution you that forward-looking statements are on guarantees of future performance and involve known and

This presentation includes non-IFRS financial measures, including EBITDA and Adjusted EBITDA. These measures are supplemental measures of financial performance that are not required by, or presented in accordance with, international financial reporting standards ("IFRS"). Please refer to the Appendix of this presentation for a reconciliation of such non-IFRS financial measures to the most directly comparable financial measures prepared in accordance with IFRS.





- Q3 2022 Highlights
- Key Business Initiatives
- Q3 2022 Financial Results
- Fiscal 2022 Financial Guidance
- Q&A



Fried Vancraen Founder & CEO



Peter Leys Executive Chairman



Johan Albrecht CFO

Q3 2022 Financial Highlights




- Q3 2022 revenue increased 11.7% to 58,288 kEUR from last year
- Deferred revenue from maintenance and licenses fees grew 3,214 kEUR to 38,359 kEUR compared to December 31, 2021
- Q3 2022 Adjusted EBITDA decreased to 5,072 kEUR or 8.7% of revenue
- Q3 2022 net result was 1,413 kEUR, or 2 EUR-ct. per share

Continued solid revenue growth

Redefining Aerial Surveying





60 unique end parts per drone for the company Atmos Flexibility & ability to iterate and improve parts quickly Potential to scale and iterate

Taking Footscan to the Next Level



« Huge, huge time savings. They're perfect out of the box !» - Doc Jenny Sanders



« It really is the next level of orthotics and we are so excited to get to work with it »


« Confidence that this will certainly move 3D printing to the next level»

« We are all in awe of what we have seen this week and cannot stop talking about it, the cogs are turning at great pace. So very happy and thank you and all the team once again for the excellent design»


- Testimonials of experts in the field of podiatry - GMT, UK



Q3 2022 Consolidated Revenue



Q3 2022 Revenue by Segment



- Revenue grew 11.7%, growth in all segments
- Deferred revenue from licenses and maintenance fees grew 3.2 mEUR* to 38.4 mEUR on our balance sheet
- Cross-segment revenue from software products amounted to 31%




Q3 2022 Consolidated Adjusted EBITDA



- Q3 2022 consolidated Adjusted EBITDA included:
 - the effect of continuing investments in Link3D and our other growth business lines
 - the operating investments in Identify3D, acquired on September 1, 2022
 - the effect of investment in our personnel to be able to compete in the current labor market situation
 - the effect of persistently high inflation

Q3 2022 Software Segment







- Q3 2022 revenue grew 3.8% to 10,863 kEUR, supported by sales from renewal licenses
- Q3 2022 Adjusted EBITDA included the ongoing investments in Link3D, Identify3D and CO-AM

* Sales are defined in this presentation as revenue plus deferred revenue.



Q3 2022 Medical Segment





- Q3 2022 revenue increased 13.1% to 21,391 kEUR
 - Revenue from medical software grew 19.1%; sales grew 31.7%
 - Revenue from medical device solutions grew 10.2%
- Q3 2022 Adjusted EBITDA of 4,765kEUR, 22.3% EBITDA margin
 - · Effects of sales mix, investing in growth business lines, inflation and war for talent



Q3 2022 Manufacturing Segment



- Q3 2022 revenue rose 14.1% to 26,033 kEUR
 - Solid growth in the core manufacturing business lines
- Q3 2022 Adjusted EBITDA of 2,530 kEUR, 9.7% EBITDA margin, including
 - Continued investments in our growth business
 - · Effects of inflation and pressure in the labor market
 - Higher cost of subcontracting services



Income Statement Highlights

(in thousands of euros, except where indicated)	Q3 2022	Q3 2021(*)
Revenue	58,288	52,195
Cost of sales	(26,245)	(21,119)
Gross profit	32,042	31,076
Research & development expenses	(9,313)	(6,602)
Sales & marketing expenses	(15,198)	(12,413)
General & administrative expenses	(8,980)	(7,885)
Other income/(expenses), net	1,166	355
Operating profit/(loss)	(282)	4,529
Financial income/(expenses), net	2,173	4,203
Share in gain/(loss) of joint venture	-	-
Taxes*	(478)	(75)
 Net profit/(loss)	1,413	8,657
Diluted EPS (in ε)	0.02	0.15
(Diluted) weighted average shares (thousands)	59,089	58,944

(*) The year 2021 has been restated to reflect the final accounting of the business combination with RS Print. Impact on the three months ended September 30 income taxes and net profit is 5 k€

Other Financial Highlights



(in thousands of euros)	09/30/'22	12/31/'21
Cash and equivalents	150,621	196,028
Receivables	42,329	41,541
Inventories	15,532	11,295
Payables	26,166	20,954
Deferred income	43,044	38,258
Borrowings	83,925	99,107
Equity	236,538	232,577
Total balance sheet	415,606	413,408

(in thousands of euros)	Q3 2022	Q3 2021
Capital expenditures	9,441	3,252
Cash flow from operations	3,840	4,388

APPENDIX Adjusted EBITDA Reconciliation



(in thousands of euros)	Q3 2022	Q3 2021(*)
Net profit/(loss)*	1,413	8,657
Income taxes*	478	75
Financial expenses	2,110	(2,334)
Financial income	(4,283)	(1,869)
Share of loss in a joint venture	-	-
Depreciation & amortization	5,378	5,314
EBITDA	5,096	9,843
Share-based compensation expenses	(24)	(104)
Acquisition-related expenses	-	-
Impairments	-	-
Adjusted EBITDA	5,072	9,739

(*) The year 2021 has been restated to reflect the final accounting of the business combination with RS Print. Impact on the three months ended September 30 income taxes and net profit is 5 k€